HomeCompareEMPO vs ABBV

EMPO vs ABBV: Dividend Comparison 2026

EMPO yields 500000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMPO wins by $4.663521010693878e+33M in total portfolio value
10 years
EMPO
EMPO
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full EMPO calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EMPO vs ABBV

📍 EMPO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMPOABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMPO + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMPO pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMPO
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EMPO beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMPO + ABBV for your $10,000?

EMPO: 50%ABBV: 50%
100% ABBV50/50100% EMPO
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EMPO
No analyst data
Altman Z
-1.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMPO buys
0
ABBV buys
0
No recent congressional trades found for EMPO or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMPOABBV
Forward yield500000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.663521010693878e+33M$102.3K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.6634009849658873e+33M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMPO vs ABBV ($10,000, DRIP)

YearEMPO PortfolioEMPO Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,550$430.00+$50.00MEMPO
2$233,748,371,262$233,694,859,813.08$13,472$627.96+$233748.36MEMPO
3$1,021,074,511,412,696$1,020,824,400,655,446.10$15,906$926.08+$1021074511.40MEMPO
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$19,071$1,382.55+$4168597328794.93MEMPO
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$23,302$2,095.81+$15905475114600664.00MEMPO
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$29,150$3,237.93+$56718938532531060736.00MEMPO
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$37,536$5,121.41+$1.8903180743562385e+23MEMPO
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$50,079$8,338.38+$5.8879981047651824e+26MEMPO
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$69,753$14,065.80+$1.7140642681147225e+30MEMPO
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.663521010693878e+33MEMPO

EMPO vs ABBV: Complete Analysis 2026

EMPOStock

Empowered Products, Inc., together with its subsidiaries, manufactures, sells, and distributes personal care products principally in the United States, Europe, and Asia. It provides various products, including topical gels, lotions, and oils, which are designed to enhance a person's mental focus and to improve the bond of interpersonal relationships. The company sells 12 formulated skin lubricants under PINK for women and GUN OIL for men trademarks. It offers various products for men, such as GUN OIL Silicone, a silicone-based interactive lubricant; GUN OIL H2O, a water-based interactive lubricant; GUN OIL Force Recon, a combination water and silicone interactive lubricant; GUN OIL Gel, a gelatinous lubricant for men's personal toys; GUN OIL Stroke 29, a self-applied men's personal lubricant; GUN OIL Loaded, a silicone infused cream hybrid interactive lubricant; GUN OIL Jack Jelly, a self-applied men's personal lubricant in gelatinous form; and GUN OIL Shine, a personal toy cleaner. The company also provides products for women comprising PINK Silicone, an interactive lubricant with silicone vitamin E and aloe vera; PINK Water, a water-based interactive lubricant with vitamin E and aloe vera; Hot PINK, an exothermic massage lubricant; PINK Frolic, a women's personal toy lubricant; PINK Unity, a gelatinous hybrid lubricant with silicone and water; PINK Indulgence Crème, a hybrid cream interactive lubricant; and PINK Sparkle, a personal toy cleaner. Empowered Products, Inc. sells its products directly to retailers, as well as to consumers through its online Wellness Stores. The company is headquartered in Las Vegas, Nevada.

Full EMPO Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EMPO vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMPO vs SCHDEMPO vs JEPIEMPO vs OEMPO vs KOEMPO vs MAINEMPO vs JNJEMPO vs MRKEMPO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.